-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Moderna And University Of Oxford Receive UK MHRA Authorization To Begin Phase 1/2 Study Of mRNA Cancer Vaccine For Lynch Syndrome

Benzinga·06/09/2026 08:09:13
Listen to the news
  • Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]
  • The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention